Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Divis Laboratories Ltd

₹ 6,6420.00%
07 Jan – close price
🔗divislabs.com•BSE: 532488•NSE: DIVISLAB
Market Cap₹ 1,76,292 Cr.
Current Price₹ 6,642
High / Low₹ 7,078
Stock P/E70.1
Book Value₹ 578
Dividend Yield0.45 %
ROCE20.6 %
ROE15.6 %
Face Value₹ 2.00
Sales₹ 9,850 Cr.
OPM33.2 %
Mar Cap₹ 1,76,292 Cr.

ABOUT

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

KEY POINTS

Business Overview:[1]Company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:a)Generic APIs:[2]Company manufactures 30 Large Volume Generic APIs in10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Further, there are 10 APIs in various stages of R&D and pilot scale developmentb)Custom Synthesis:[3]Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ yearsc)Nutraceutical:[4][5]Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1782.6037.05427717.600.903124.952.5614478.318.9320.2154964.0130.1211543.963117.955.5012.970.07
2.Divi's Lab.6642.5070.12176292.380.45696.0034.362660.0015.5520.659850.0033.162514.00696.0011.4913.720.01
3.Torrent Pharma.4092.2063.93138496.880.78591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.3913.260.33
4.Cipla1467.9021.80118607.610.891353.373.737589.447.6422.7228349.5725.405441.141351.173.6014.720.01
5.Dr Reddy's Labs1242.8017.97103748.510.641336.807.288828.309.8322.6934310.0024.645772.201347.102.8812.950.16
6.Lupin2214.3023.36101043.200.541484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1512.410.32
7.Mankind Pharma2311.8054.5595387.580.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.248.890.55
–Median: 150 Co.409.6730.811757.370.1113.0312.32157.210.8414.98582.8715.9644.5513.733.158.60.22

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
1,6901,8082,2971,7302,0632,3571,9082,2592,5361,8231,8682,3022,660
Expenses
1,2801,3171,5501,2391,4421,6141,4191,5421,6551,2141,3941,5731,765
Operating Profit
409491747491621743489717881609474729895
Other Income
116948280791196679877985105146
Profit before tax
439490730478603747468700861603464735920
Tax %
29%27%19%28%29%25%32%24%23%19%26%30%24%
Net Profit
311358594345430557319531667487342518696
EPS in Rs
11.7113.4922.3813.0016.2020.9812.0220.0025.1318.3412.8819.5126.22

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
2,5143,0843,7204,0243,8164,8805,3116,7998,8807,6257,6659,1989,850
Expenses
1,4921,9142,3142,5822,5583,0283,4913,9715,0005,2755,4866,2146,584
Operating Profit
1,0221,1701,4061,4411,2581,8511,8202,8283,8802,3502,1792,9843,266
Other Income
8136927310615518757109348333348434
Interest
33432572224211
Depreciation
92136118123142169186255311342376401431
Profit before tax
1,0091,0671,3751,3881,2191,8331,8132,6283,6772,3542,1322,9293,258
Net Profit
7928471,1111,0538701,3331,3731,9552,9491,8081,5762,2092,514
EPS in Rs
29.8231.9041.8439.6832.7650.2051.7173.63111.0768.1159.3783.2194.71
Dividend Payout %
34%31%24%25%31%32%31%27%27%44%50%36%–

Compounded Profit Growth

10 Years:10%
5 Years:11%
3 Years:-9%
TTM:37%

Compounded Sales Growth

10 Years:12%
5 Years:12%
3 Years:1%
TTM:17%

Return on Equity

10 Years:19%
5 Years:18%
3 Years:14%
Last Year:16%

Stock Price CAGR

10 Years:19%
5 Years:11%
3 Years:25%
1 Year:12%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
27275353535353535353535353
Reserves
3,0083,5354,3045,3565,9076,9207,2649,21811,63812,65213,43114,84215,298
Borrowings
1827423663106340000289
Other Liabilities
7318865667657859611,1641,4521,6171,6471,8781,9272,635
Total Liabilities
3,7844,4754,9656,2106,8088,0408,51410,72413,30814,35215,36216,82418,075
Fixed Assets
1,2221,3091,4391,5591,9962,0872,7763,6994,3214,7194,7375,4405,675
Gross Block
1,739.791,952.402,195.421,793.572,372.922,633.293,508.064,685.465,617.696,358.006,752.007,859.00–
Accumulated Depreciation
518.19643.67756.78234.62377.04545.85731.80986.451,296.721,639.002,015.002,419.00–
CWIP
1442182644441204929207114702127781,0222,030
Investments
5057368131,6391,8971,95397977984897274
Other Assets
1,9132,2122,4502,5682,7953,5083,8396,3078,4389,3379,75810,29010,296
Total Assets
3,7844,4754,9656,2106,8088,0408,51410,72413,30814,35215,36216,82418,075

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
5588221,0361,1497659641,2081,9471,9102,4471,2661,650
Cash from Investing Activity
-305-521-411-1,137-476-684-8175-2,195-2,707-268-803
Cash from Financing Activity
-248-303-6303-314-246-1,091-34-532-796-798-797
Net Cash Flow
5-1-515-2534361,988-817-1,05620050

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
115979591106961059410694108113
Inventory Days
355335284291311324299322316329347296
Days Payable
59675610398949911892889486
Cash Conversion Cycle
411365323280319325305298330335361323
Working Capital Days
162146165153185173184155178190207193
ROCE %
36%32%35%28%21%28%24%32%35%19%16%21%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
51.94%51.94%51.93%51.93%51.92%51.92%51.89%51.89%51.89%51.89%51.88%51.88%
FIIs
15.15%14.67%14.69%14.60%14.85%14.68%16.16%17.25%17.98%18.01%19.74%19.39%
DIIs
20.62%21.00%21.15%21.65%21.78%22.10%21.66%20.98%20.44%20.63%18.96%19.68%
Public
12.23%12.31%12.13%11.72%11.33%11.19%10.17%9.79%9.58%9.39%9.32%8.96%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Indian Pharma Sector Shows Resilience Amidst Tariff Concerns, Selective Growth Predicted

7th April 2026, 9:07 pm

Divi's Labs Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026

6th April 2026, 8:47 pm

Divi's Laboratories to Close Trading Window from April 1, 2026, Ahead of Financial Results

31st March 2026, 3:32 pm

Divi's Labs Receives Draft Income Tax Order Proposing ₹570.51 Cr Additions

21st March 2026, 9:47 pm

Divi's Labs Announces Special Window for Physical Share Transfer and Dematerialisation

14th March 2026, 6:10 pm

Published by Other Websites

External media mentions & references

India Pharma Stocks Hit by US 'Revlimid Cliff'; Domestic Growth Offers Lifeline

15th April 2026, 8:01 am

India's Biopharma SHAKTI: Syngene, Biocon, Divi's Take Different Routes

11th April 2026, 7:56 am

US Tariffs Force Indian Drugmakers to Rethink Supply Chains

8th April 2026, 2:58 pm

US Tariffs Hit Pharma Stocks, Nifty Healthcare Dives Below Support

6th April 2026, 11:41 am

Trump's 100% Drug Tariffs Hit India's Innovative Pharma Sector

6th April 2026, 10:31 am

News Articles

Editorial & research coverage

Divi's Lab Q3: Custom Synthesis Fuels Growth, Peptide Power Beckons
Divi's Lab Q3: Custom Synthesis Fuels Growth, Peptide Power Beckons

12th February 2026, 11:38 am

Budget Schemes Boost India's Chemical & Pharma Sectors
Budget Schemes Boost India's Chemical & Pharma Sectors

1st February 2026, 4:35 pm

Bajaj Finance AMC Adjusts Flexi and Large Cap Portfolios Amidst Market Dynamics
Bajaj Finance AMC Adjusts Flexi and Large Cap Portfolios Amidst Market Dynamics

22nd January 2026, 4:36 pm

Indian Pharma Q3: Revenue Steady, Profits Lag on US Generics & Rising Costs
Indian Pharma Q3: Revenue Steady, Profits Lag on US Generics & Rising Costs

21st January 2026, 12:39 pm

India Pharma CRDMOs Poised for APAC Dominance: HDFC Securities Initiates Coverage
India Pharma CRDMOs Poised for APAC Dominance: HDFC Securities Initiates Coverage

9th January 2026, 11:23 am

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window

31 Dec - Trading window closed Jan 1, 2026 until 48 hours after unaudited Q3/9M results for Dec 31, 2025.

Regulation 30 Disclosure - US-FDA Inspection Of Company'S Unit-I Manufacturing Facility At Lingojigudem Village, Yadadri Bhuvanagiri District, Telangana, India

14 Nov 2025 - Unit-I (Lingojigudem, Telangana) US-FDA cGMP inspection Nov 10–14, 2025 concluded with no 483 observations.

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

12 Nov 2025 - Submission of transcript of Q2FY26 earnings conference call held on November 07, 2025.

Announcement under Regulation 30 (LODR)-Newspaper Publication

8 Nov 2025 - Newspaper clippings regarding unaudited financial results for the quarter and half year ended September 30, 2025

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from nse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Credit Ratings

Rating update

26 Aug 2025 from care

Rating update

13 Sep 2024 from care

Rating update

12 Sep 2023 from care

Rating update

4 Oct 2022 from care

Rating update

5 Oct 2021 from care

Rating update

26 Aug 2021 from care

Concalls

Nov 2025

TranscriptRecording

Aug 2025

Transcript

May 2025

Transcript

Feb 2025

TranscriptRecording

Nov 2024

TranscriptRecording

Aug 2024

TranscriptRecording

May 2024

TranscriptRecording

May 2024

Recording

Feb 2024

TranscriptRecording

Nov 2023

Transcript

Nov 2023

Transcript

Aug 2023

TranscriptRecording

May 2023

TranscriptRecording

Feb 2023

Transcript

Nov 2022

Transcript

Aug 2022

Transcript

May 2022

Transcript

Feb 2022

Transcript

Nov 2021

Transcript

May 2021

Transcript

Jan 2021

Transcript

Oct 2020

Transcript

Aug 2020

Transcript

May 2020

Recording

Mar 2017

Transcript

Stock Analysis

Description

  1. Divi's Laboratories Limited is a prominent Indian pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), intermediates, and custom synthesis services for global markets.

Key Growth Triggers

  1. Robust momentum in custom synthesis and peptide business segments.
  2. Strategic capacity expansions, including the commencement of Unit-3 Phase I in Kakinada.
  3. Continued investment in Research & Development and new technologies (flow chemistry, biocatalysis).
  4. Positive industry outlook for APIs and Contract Development and Manufacturing Organizations (CDMOs).
  5. Anticipated commercial contribution from new projects within the next 1-2 years.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Currently no data available for Key Red Flags.

Key Dates To Watch

  1. November 07, 2025: Board Meeting for Q2 FY26 Results and Earnings Conference Call.
  2. November 10-14, 2025: US-FDA inspection of Unit-I facility.
  3. January 01, 2026: Trading window closure for Q3 FY26 results.
  4. January 03, 2026: Submission of Q4 2025 compliance certificate.

Corporate Announcements

7th Apr 26
Impact Rating: -
No description available.
6th Apr 26
Impact Rating: 1
Divi's Laboratories Limited filed its routine compliance certificate for the quarter ended March 31, 2026, under SEBI regulations. This filing from KFin Technologies confirms proper processing of dematerialized securities and cancellation of old certificates.
31st Mar 26
Impact Rating: 6
Divi's Laboratories announced the closure of its trading window for insiders from April 1, 2026. This period will last until 48 hours after the declaration of its audited financial results for the fiscal year ending March 31, 2026.
21st Mar 26
Impact Rating: 7
Divi's Laboratories has disclosed a Draft Income Tax Order for FY2022-23 from the IT department, proposing ₹570.51 crores in additions due to Transfer Pricing and corporate tax adjustments.
14th Mar 26
Impact Rating: -
No description available.